• Philippe Morice, Giovanni Scambia, Nadeem R Abu-Rustum, Maribel Acien, Alessandro Arena, Sara Brucker, Ying Cheong, Pierre Collinet, Francesco Fanfani, Francesca Filippi, Ane Gerda Zahl Eriksson, Sebastien Gouy, Philipp Harter, Xavier Matias-Guiu, George Pados, Maja Pakiz, Denis Querleu, Alexandros Rodolakis, Christine Rousset-Jablonski, Artem Stepanyan, Antonia Carla Testa, Kirsten Tryde Macklon, Dimitrios Tsolakidis, Michel De Vos, François Planchamp, and Michaël Grynberg.
• Department of Gynecological Surgery, Gustave Roussy Cancer Campus, Villejuif, France; Université Paris Saclay, Paris, France. Electronic address: philippe.morice@gustaveroussy.fr.
• Lancet Oncol. 2024 Nov 1; 25 (11): e602e610e602-e610.

AbstractThe European Society of Gynaecological Oncology, the European Society of Human Reproduction and Embryology, and the European Society for Gynaecological Endoscopy jointly developed clinically relevant and evidence-based guidelines focusing on key aspects of fertility-sparing strategies and follow-up of patients with cervical cancers, ovarian cancers, and borderline ovarian tumours. The developmental process of these guidelines is based on a systematic literature review and critical appraisal involving an international multidisciplinary development group consisting of 25 experts from relevant disciplines (ie, gynaecological oncology, oncofertility, reproductive surgery, endoscopy, imaging, conservative surgery, medical oncology, and histopathology). Before publication, the guidelines were reviewed by 121 independent international practitioners in cancer care delivery and patient representatives. The guidelines comprehensively cover oncological aspects of fertility-sparing strategies during the initial management, optimisation of fertility results and infertility management, and the patient's desire for future pregnancy and beyond.Copyright © Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.

26 keywords...

hide…